Legal Opinion
Santarus, Inc. v. Par Pharmaceutical, Inc.
Court of Appeals for the Federal Circuit
Decided September 4, 2012No. 2010-1360, 2010-1380PublishedCited by 44 opinions
1Opinion of the Court
Opinion for the court filed PER CURIAM. Opinion concurring in part and dissenting in part filed by Circuit Judge NEWMAN.
2Per curiam
Appeal and cross-appeal are taken from the judgment of the United States District Court for the District of Delaware.1 Plaintiff Santarus, Inc. is the exclusive licensee of patents on specified formulations of benzimidazole proton pump inhibitors (PPI)— a class of chemical compounds that inhibit gastric acid secretion and help prevent and treat stomach acid-related diseases and disorders. The patents are for the inventions of Dr. Jeffrey Phillips, and are assigned to the…
3Cases cited13 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Therasense, Inc. v. Becton, Dickinson and Co.Court of Appeals for the Federal Circuit · 2011
- Medichem, S.A. v. Rolabo, S.L.Court of Appeals for the Federal Circuit · 2006
8 more not listed; retrieve them via the Exa API.
4Cited by44 opinions
- Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.Court of Appeals for the Federal Circuit · 2014
- Commonwealth Scientific & Industrial Research Organisation v. Cisco Systems, Inc.Court of Appeals for the Federal Circuit · 2015
- Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2014
- Icon Health and Fitness, Inc. v. Strava, Inc.Court of Appeals for the Federal Circuit · 2017
- Allergan, Inc. v. Sandoz Inc.Court of Appeals for the Federal Circuit · 2015
39 more not listed; retrieve them via the Exa API.